N-Phenethyl Dimethylamine Citrate
N-Phenethyl Dimethylamine Citrate is a synthetic compound belonging to the phenethylamine class of stimulants. Its mechanism of action, while not confirmed through human clinical trials, is inferred from its chemical structure and its relationship to endogenous and supplemental phenethylamines (PEAs).
PEA Backbone and Receptor Interaction
The core of the molecule is the phenethylamine 'backbone'. This structure is common to many neurotransmitters (like dopamine and norepinephrine) and stimulants (like amphetamine). This backbone allows the molecule to interact with trace amine-associated receptors (TAARs), particularly TAAR1, and potentially modulate the release and reuptake of monoamine neurotransmitters. By mimicking endogenous neurotransmitters, it can trigger a signaling cascade that results in the release of dopamine and norepinephrine from presynaptic vesicles into the synapse, leading to increased neuronal firing and the subjective feelings of stimulation, focus, and euphoria.
Protection from Monoamine Oxidase (MAO) Degradation
Standard, unsubstituted Phenethylamine (PEA) is a very poor oral supplement on its own because it is a prime substrate for the enzyme Monoamine Oxidase-B (MAO-B) (EC 1.4.3.4), which is highly concentrated in the gut and liver. This first-pass metabolism rapidly deaminates PEA, rendering it inactive, typically within 5-10 minutes of ingestion. The defining feature of N-Phenethyl Dimethylamine is the presence of two methyl groups attached to the terminal nitrogen of the ethylamine side chain (N,N-dimethyl). This structural modification is hypothesized to provide steric hindrance, effectively 'shielding' the amine group from the active site of the MAO enzyme. This resistance to enzymatic degradation allows a greater concentration of the compound to pass into systemic circulation, cross the blood-brain barrier, and exert its effects on the central nervous system for a significantly longer duration than standard PEA.
Pharmacokinetics
The provided sources contain no information on the pharmacokinetics of N-Phenethyl Dimethylamine Citrate in humans. Key parameters such as oral bioavailability, time to maximum plasma concentration (Tmax), volume of distribution, and elimination half-life (t1/2) have not been clinically determined. The duration of its effects is anecdotally reported to be longer than PEA but shorter than more potent, restricted stimulants.